首页 » AML-venetoclax NTCC®人急性髓系白血病细胞维奈克拉耐药细胞株resistant cell line BioVector NTCC细胞保藏中心

AML-venetoclax NTCC®人急性髓系白血病细胞维奈克拉耐药细胞株resistant cell line BioVector NTCC细胞保藏中心

  • 价  格:¥998950
  • 货  号:NTCC® AML-venetoclax
  • 产  地:北京
点击询问我要采购
 竭诚为您服务!
BioVector NTCC典型培养物保藏中心
联系人:Dr.Xu, Biovector NTCC Inc.

电话:400-800-2947 工作QQ:1843439339 (微信同号)

邮件:Biovector@163.com

手机:18901268599

地址:北京

已注册
 

AML-venetoclax NTCC®人急性髓系白血病细胞维奈克拉耐药细胞株resistant cell line

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心


AML-venetoclax resistant cell line is a type of laboratory-grown cell that has developed the ability to survive and proliferate despite being exposed to venetoclax, a drug used to treat acute myeloid leukemia (AML). These cell lines are valuable research tools because they can help scientists understand the mechanisms of venetoclax resistance and identify potential strategies to overcome it.


Several mechanisms of venetoclax resistance have been identified in AML cell lines, including:

  • Increased expression of MCL1:MCL1 is a protein that can inhibit apoptosis, or programmed cell death. When MCL1 levels are high, it can counteract the effects of venetoclax, which works by promoting apoptosis in AML cells.


  • Mutations in BCL2:BCL2 is the protein that venetoclax targets.Mutations in BCL2 can make it less susceptible to venetoclax, allowing AML cells to survive.


  • Changes in mitochondrial function: Mitochondria are the "powerhouses" of cells.Changes in mitochondrial function can help AML cells resist apoptosis, even in the presence of venetoclax.


AML-venetoclax resistant cell lines are being used to study these mechanisms of resistance and to develop new drugs and therapies that can overcome them. For example, researchers are investigating the use of MCL1 inhibitors in combination with venetoclax to target AML cells that have become resistant to venetoclax alone.


In addition to their use in basic research, AML-venetoclax resistant cell lines can also be used to:

  • Test new drugs and therapies: Researchers can use these cell lines to screen new drugs and therapies for their ability to kill AML cells that are resistant to venetoclax.

  • Develop personalized treatment plans: By understanding the specific mechanisms of resistance in a patient's AML cells, researchers may be able to develop personalized treatment plans that are more likely to be effective.

Venetoclax-Resistant MV4-11 Leukemic Cells Activate PI3K/AKT Pathway for  Metabolic Reprogramming and Redox Adaptation for Survival

MO-91 Acute Myeloid Leukemia w Minimal Differentiation Human Cell Line |  Sigma-Aldrich


生产厂家Supplier:

BioVector NTCC质粒载体菌株细胞蛋白抗体基因保藏中心

E-mail:BioVector@163.com


http://www.biovector.net


您正在向 biovector.net  发送关于产品 AML-venetoclax NTCC®人急性髓系白血病细胞维奈克拉耐药细胞株resistant cell line BioVector NTCC细胞保藏中心 的询问

点击“立即发送”后,我们将在1个工作日内与您取得联系。